Evidence map›Paper›PMID 40202909›Full record

ArticleACS applied bio materials2025

Core-Shell UCNP@MOF Nanoplatforms for Dual Stimuli-Responsive Doxorubicin Release.

Marina P Abuçafy, Beatriz B S Ramin, Angelica E Graminha, Willy G Santos, Regina C G Frem, Adelino V G Netto, José Clayston M Pereira, Sidney J L Ribeiro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marina P AbuçafyInstitute of Chemistry, São Paulo State University, Araraquara, São Paulo 14800-060, Brazil.ORCID 0000-0001-8247-2092
Beatriz B S RaminInstitute of Chemistry, São Paulo State University, Araraquara, São Paulo 14800-060, Brazil.
Angelica E GraminhaInstitute of Chemistry, São Paulo State University, Araraquara, São Paulo 14800-060, Brazil.
Willy G SantosInstitute of Chemistry, São Paulo State University, Araraquara, São Paulo 14800-060, Brazil.
Regina C G FremInstitute of Chemistry, São Paulo State University, Araraquara, São Paulo 14800-060, Brazil.ORCID 0000-0003-1574-681X
Adelino V G NettoInstitute of Chemistry, São Paulo State University, Araraquara, São Paulo 14800-060, Brazil.
José Clayston M PereiraInstitute of Chemistry, São Paulo State University, Araraquara, São Paulo 14800-060, Brazil.
Sidney J L RibeiroInstitute of Chemistry, São Paulo State University, Araraquara, São Paulo 14800-060, Brazil.ORCID 0000-0002-8162-6747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanocarrier systems with multifunctional capabilities hold great potential for targeted cancer therapy, particularly for breast cancer treatment. Metal-organic frameworks (MOFs) are notable for their high porosity and, in some cases, biocompatibility, with ZIF-8 being particularly advantageous due to its pH-sensitive degradability, enabling selective drug release in tumor environments. Additionally, lanthanide-doped upconversion nanoparticles (UCNPs) offer unique optical properties that enhance both imaging and therapeutic applications. In this study, NaYF

Indexed as

Antibiotics, AntineoplasticAntineoplastic AgentsBiocompatible MaterialsDoxorubicinDrug CarriersMetal-Organic FrameworksNanoparticlesCell ProliferationCell SurvivalDrug LiberationDrug Screening Assays, AntitumorHumansHydrogen-Ion ConcentrationMaterials TestingMCF-7 CellsParticle SizeAntibiotics, AntineoplasticAntineoplastic AgentsBiocompatible MaterialsDoxorubicinDrug CarriersMetal-Organic Frameworkslaser stimulationmetal−organic frameworksmultifunctional nanocarrier systemspH-sensitive drug releaseupconversion nanoparticles

Identifiers

PMID40202909
PMCPMC12015952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.